Mechanisms Underlying the Selection and Function of Macrophage-Specific Enhancers

VERENA M. LINK,^{1,2} DAVID GOSSELIN,¹ AND CHRISTOPHER K. GLASS^{1,3}

¹*Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California 92093-0651*

²*Faculty of Biology, Department II, Ludwig-Maximilians Universität München, Planegg-Martinsried 82152, Germany*

³*Department of Medicine, University of California, San Diego, La Jolla, California 92093-0651*

Correspondence: ckg@ucsd.edu

Macrophages populate every tissue of the body and play vital roles in homeostasis, pathogen elimination, and tissue healing. These cells possess the ability to adapt to a multitude of abruptly changing and complex environments. Furthermore, different populations of resident tissue macrophages each show their own defining gene signatures. The enhancer repertoire of these cells underlies both the cellular identity of a given subset of resident macrophage population and their ability to dynamically alter, in an efficient manner, their gene expression programs in response to internal and external signals. Notably, transcription is pervasive at active enhancers and enhancer RNAs, or eRNAs, are tightly correlated to regulated transcription of protein-coding genes. Furthermore, selection and establishment of enhancers is a dynamic and plastic process in which activation of intracellular signaling pathways by factors present in a macrophage's environment play a determining role. Here, we review recent studies providing insights into the distinct mechanisms that contribute to the selection and function of enhancers in macrophages and the relevance of studying these mechanisms to gain a better understanding of complex human diseases.

Macrophages are fundamental effectors of the innate immune system (Geissmann et al. 2010). Their capacity to abruptly and dramatically alter their gene expression output to quickly adapt to sudden changes in their environment, as it occurs during infections or tissue injuries, makes them one of the most dynamic cell types transcriptionally. In addition, each subset of resident tissue macrophages performs dedicated and specialized functions, as illustrated, for example, by the role of microglia in promoting adult neurogenesis (Sierra et al. 2010) and that of large peritoneal macrophages in regulating production of IgA in B-1 cells (Okabe and Medzhitov 2014). Although the overall transcriptome signature across different macrophage populations displays substantial similarities that define a core macrophage identity (Gautier et al. 2012), specific populations also show striking differences in expression of subsets of genes that are presumably linked to their tissue-specific functions. For example, microglia express ~900 mRNAs at more than a 16-fold higher level than observed in large peritoneal macrophages, and a similar number of genes are expressed at more than a 16-fold higher level in large peritoneal macrophages than microglia (Gosselin et al. 2014). As macrophages can originate from different precursors (Ginhoux et al. 2010; Hoeffel et al. 2012; Schulz et al. 2012; Williams et al. 2013; Epelman et al. 2014; Ginhoux and Jung 2014), an important question is the extent to which the characteristics of different tissue resident populations of macrophages reflect the specific tissue environment or their developmental histories.

From a transcriptional perspective, the concept of subset identity is rather intriguing, as macrophages, for any given individual, share the same genome and express to a great extent the same array of transcription factors (TFs). The recent development of massively parallel sequencing assays has made it possible to characterize TF binding and chromatin features on a genome-wide level. A major concept to emerge from these approaches is that each cell type selects a specific repertoire of discrete DNA regulatory elements, termed enhancers, that are critical to that cell's identity and determine its ability to respond to internal and external signals (Heinz et al. 2015). Here, we discuss mechanisms that underlie the selection and activation of enhancers and their relationship to the development of tissue-specific macrophage phenotypes.

ENHANCERS AS DETERMINANTS OF CELL-SPECIFIC AND SIGNAL-DEPENDENT GENE EXPRESSION

Enhancers were initially identified as discreet regions of DNA that increase transcriptional activity of promoters from a distance (Banerji et al. 1981). Systematic analysis of the genome led to the recognition that enhancers are marked by high abundance of monomethylation at histone H3 lysine 4 and concomitantly low levels of trimethylation (i.e., H3K4me1^{high}/H3K4me3^{low}) (Heintzman et al. 2007). Promoters, on the other hand, display an opposite molecular phenotype (i.e., H3K4me1^{low}/H3K4me3^{high}). Both promoters and enhancers are also marked by high

abundance of dimethylation at histone H3 lysine 4 (H3K4me2). Active enhancers and promoters also show enrichment of acetylation at histone H3 lysine 27 (H3K27ac) (Creyghton et al. 2010). Further, enhancers can be actively repressed with high levels of trimethylation of histone H3 lysine 27 (H3K27me3) (Barski et al. 2007; Calo and Wysocka 2013). These, and other features, enable enhancer-like regions to be identified systematically in different cells and tissues by chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq) and other sequencing-based methods. Using these approaches, the mouse and human genomes have been estimated to contain several hundred thousand enhancers, the great majority of which are present in cell-restricted patterns (ENCODE Project Consortium 2012).

More recently, the concept of stretch or super-enhancers (SEs) were introduced (Hnisz et al. 2013; Whyte et al. 2013): large genomic regions, usually one order of magnitude larger than traditional enhancers with an unusually strong enrichment for the binding of transcriptional coactivators. Most cells show between 300 and 800 SEs, a substantial fraction of which are associated with genes encoding cell type-specific TFs and other genes important for that cell's identity and function (Hnisz et al. 2013; Adam et al. 2015).

Between 35,000 and 45,000 H3K4me1^{high}/H3K4me3^{low} enhancer regions exist in mouse macrophages (Ghisletti et al. 2010; Heinz et al. 2010), substantially exceeding the ~12,000 active promoters in these cells. Of note, DNA sequences at enhancers in macrophages show a robust enrichment for motifs recognized by TFs relevant to macrophage ontogeny and functions. Among these, the motif recognized by the ETS family member PU.1 is predominant, which is concordant with the observation that PU.1 binding sites genome-wide (i.e., the PU.1 cistrome) extensively coincide with H3K4me1^{high}/H3K4me3^{low} regions in macrophages. Motifs associated with C/EBP, AP-1, IRF, NF- κ B, and LXR TFs are also prevalent within enhancers in macrophages (Barish et al. 2010; Ghisletti et al. 2010; Heinz et al. 2010; Gosselin et al. 2014; Lavin et al. 2014).

Such co-occurrences of motifs belonging to different families of TFs indicate that enhancers provide sites for the integration at the genomic level of TFs regulated by cell intrinsic and/or extrinsic signals. Furthermore, given the preponderance of enhancers compared with promoters, these interactions between TFs and DNA are more likely to occur at enhancers than at promoters. Therefore, this characteristic enables a key effector mechanism by which enhancers can synchronize the transcriptional output of a macrophage in accordance with its cellular activity and metabolism.

A COLLABORATIVE/HIERARCHICAL MODEL FOR ENHANCER SELECTION AND ACTIVATION

Enhancer selection is mediated by the activities of so-called pioneer factors, a subset of which function

as lineage-determining transcription factors (LDTFs) (McPherson et al. 1993; Bossard and Zaret 1998; Lee et al. 2005; Heinz et al. 2010). Various examples of LDTFs include PU.1 in macrophages (Heinz et al. 2010) and FoxA1 in breast cancer cells (Lupien et al. 2008). A defining feature of pioneering TFs is their ability to recognize and bind their DNA recognition motifs in closed chromatin, thus effectively competing with nucleosomes to create nucleosome-free regions. TF binding is then followed by modifications of the histone tails of the enhancer-associated nucleosomes located in the vicinity of the nucleosome-free regions.

All TFs recognize short DNA sequences (~6–12 bp) and their motifs show varying levels of degeneracy (D'haeseleer 2006). ChIP-seq experiments allow the identification of regions in the genome that are bound by TFs (Johnson et al. 2007). Analyses of a wide variety of different TFs have shown that only a small subset of possible binding sites is occupied by the TF (Carr and Biggin 1999; Iyer et al. 2001; Yang et al. 2006). For example, given the size of the mouse genome, there are potentially between 650,000 and 1.4 million sites where PU.1 can bind DNA on a spectrum of different stringencies (Heinz et al. 2013; Barozzi et al. 2014), yet only about up to 45,000 of those are selected in differentiated macrophages (Heinz et al. 2010).

There are likely a multitude of factors contributing to these restricted, yet functional, binding events of LDTFs. Among these factors, the collaborative activity between LDTFs and other TFs appear to be fundamental to a significant proportion of actual LDTF binding (Fig. 1A). For example, the TF PU.1 is an important LDTF in macrophages and B cells. ChIP-seq experiments showed that macrophage-specific enhancers are enriched for binding motifs of PU.1 and macrophage-specific collaborative factors C/EBP and AP-1 family members, whereas in B cells specific enhancers are enriched for PU.1 and B cell-specific factors E2A, EBF1, and Oct2 (Ghisletti et al. 2010; Heinz et al. 2010). Furthermore, macrophage-specific enhancers are depleted of the DNA binding motifs for B cell-specific LDTFs and vice versa (Heinz et al. 2010).

Using natural genetic variation across different mouse strains as a means to achieve “mutagenesis” screening in vivo, we provided functional evidence supporting the involvement of collaborative binding of TFs in the selection of actual LDTF binding in macrophages (Heinz et al. 2013). These studies showed that mutations in a C/EBP motif abrogates not only C/EBP binding, but also impairs the neighboring PU.1-DNA interactions. Similar observations were made in the case of mutations in AP-1 motifs. Importantly, such mutations also disrupted the molecular phenotype of the associated enhancer (i.e., decreased abundance of H3K4me2 mark at mutated enhancers), thus making the PU.1–C/EBP and PU.1–AP-1 collaborative activity a critical determinant of enhancer selection in macrophages. Last, we note that the natural genetic variation approach was recently extended to human white adipose tissue cells to show that mutations in C/EBP motifs disrupted nearby PPAR γ binding in those cells (Soccio et al. 2015).

Figure 1. Schematic overview of a “collaborative/hierarchical” model for macrophage enhancer selection and function. (A) Enhancers are initially selected by “collaborative” interactions of lineage-determining transcription factors (LDTFs) at regions of the genome that contain closely spaced binding sites for these factors. The term collaborative is meant to indicate that each factor requires the other to effectively compete with nucleosomes and establish a nucleosome-free region. (B) Preexisting enhancers are primary sites of action of signal-dependent transcription factors (SDTFs), here illustrated for the p65 component of NF-κB following macrophage activation by lipopolysaccharide (LPS). The dependence of SDTFs on preexisting binding of LDTFs establishes a hierarchical relationship that enables cell-specific functions of widely expressed transcription factors.

Macrophages, among many other cell types, possess the ability to quickly adapt their gene expression outcome after a change in environment. Further, the same signal can lead to the induction of the same signal-dependent transcription factor (SDTF) but different transcriptional outcomes in different cell types. Recent studies showed that in >60%, SDTFs bind to enhancers already established by LDTFs, explaining how the same broadly expressed SDTF can exert cell-specific functions and responses (Fig. 1B). Indeed, investigating the role of natural genetic variation between inbred mouse strains on binding of NF-κB p65, showed that 34% of mouse strain-specific p65 binding was due to mutations in LDTF motifs, whereas only 9% was due to mutations in the p65 binding motif itself (Heinz et al. 2013).

The nature of biochemical events associated with the collaborative model of actual LDTFs binding events is not well understood. Typically the motifs of the collaborative factors can be found in close proximity to each other in sequence (<100 bp), but most of these are not found at a distance of <20 bp (Kazemian et al. 2013), implicating a collaborative model that is not strictly dependent on protein–protein interactions. Importantly however, these restrictions address three key issues with regard to enhancer selection. One, it eliminates, for a given LDTF, numerous potential binding sites in the genome (i.e., those without nearby motifs for collaborative

factors). In addition, it provides a molecular and epigenetic mechanism whereby the same LDTF can set up very different enhancer repertoires in different cell types, as is the case of PU.1 in macrophages and B cells (mentioned above). Finally it explains how broadly expressed SDTF can result in different cell-specific transcriptional outcomes (mentioned above).

DE NOVO/LATENT ENHANCERS

Although the majority of signal-dependent responses are mediated by activation of preexisting enhancers and promoters, some signals can also be associated with the selection of new enhancers. For instance, TLR4 activation in mouse macrophages leads to a gain of de novo H3K4me1 marks at 1000–3000 discrete regions in the genome compared with unstimulated macrophages (Kaikkonen et al. 2013; Ostuni et al. 2013). Similar epigenomic remodeling occurred in response to the activation of other cytokine signaling pathways, including the interferon γ (IFN- γ)–STAT1 and the interleukin 4 (IL-4)–STAT6 axes (Ostuni et al. 2013). These new enhancer-like regions have been referred to as “de novo” or “latent enhancers.” In the case of de novo enhancers selected in response to TLR4 activation, the p65 component of NF-κB was observed to participate in collaborative binding interactions with PU.1 (Kaikkonen et al. 2013; Ostuni et al. 2013). Importantly, many of these latent enhancers appear to persist in time and correlative evidence suggests that they may possess some functionality. Indeed, 72 h following an initial IL-4 stimulation, a second stimulation leads to quicker activation of the de novo gained enhancers, as assessed by H3K27ac, compared with the first stimulation (Kaikkonen et al. 2013; Ostuni et al. 2013).

ACTIVE ENHANCERS ARE SITES OF TRANSCRIPTIONAL INITIATION

DNA regulatory elements exist in one state at any given time: active (H3K4me1^{high}, H3K4me2^{high}, H3K27ac^{high}), primed (H3K4me1^{high}, H3K4me2^{high}), actively silenced (DNA methylation), or poised/repressed (H3K27me3^{high}). Intriguingly, compelling evidence suggests that RNA polymerase II–mediated transcription occurs at active enhancers, yielding enhancer RNAs (eRNAs). Indeed, upon binding of activating SDTFs at enhancers, including nuclear receptors and NF-κB, eRNAs are rapidly synthesized and their expression levels correlate strongly with corresponding signal-dependent transcriptional changes of nearby genes (Ernst et al. 2011; Hah et al. 2011; Kaikkonen et al. 2013; Step et al. 2014). Similarly, eRNA transcription correlates positively with enhancer–promoter spatial interactions; enhancers that interact frequently with promoters through chromatin looping show higher levels of eRNA transcripts (Li et al. 2013). Although the functional significance of enhancer transcription remains poorly understood, studies on macrophages suggest two poten-

tial roles. First, enhancer transcription at newly selected signal-dependent enhancers was linked to the deposition of H3K4me1/2 at these locations (Kaikkonen et al. 2013; Ostuni et al. 2013). Thus enhancer transcription may be important in initiating and/or maintaining the histone signature characteristic of enhancers. Second, at least some eRNAs appear to contribute to enhancer function. With regard to this latter point, we recently found that the Rev-Erb nuclear receptors actively repress gene transcription in mouse macrophages by inhibiting eRNA transcription of target enhancers (Lam et al. 2013). In particular, binding of Rev-erbs at enhancers regulating *Mmp9* and *Cx3cr1* gene expression represses enhancer activity and eRNA transcription, and is associated with low levels of *Mmp9* and *Cx3cr1* mRNAs. Presumably, this likely occurs through the recruitment of the NCoR–HDAC3 repressor complex (Zamir et al. 1996; Yin and Lazar 2005). However, in the absence of Rev-Erb factors, these enhancers are derepressed and transcribe high levels of eRNAs, which translates into aberrant increase of *Mmp9* and *Cx3cr1* gene expression.

CELL IDENTITY AND ENHANCER REPERTOIRE IS LINKED TO INTEGRATION OF ENVIRONMENT SIGNAL WITH GENOME

The observation that treatment of macrophages with TLR4 agonists or IL-4 *in vitro* could drive selection of new enhancers (Kaikkonen et al. 2013; Ostuni et al. 2013) suggested a basis by which macrophages residing in different tissues acquire very different patterns of gene expression. Indeed, despite the fact that every subset of resident tissue macrophages in the body depends on PU.1 activity (McKercher et al. 1996; DeKoter et al. 1998; Schulz et al. 2012), gene expression in these cells varies greatly from one subset to another (Gautier et al. 2012). However, each subset requires its own set of signaling factors and pathways to function optimally. This entails that the corresponding resident macrophage population is exposed to a defined set of signals in its environment and thus displays a defined set of activated SDTFs at any given time (Fig. 2).

We and others recently provided extensive evidence supporting the hypothesis that tissue-derived factors play an essential role in defining the identity of its resident macrophage population (Gosselin et al. 2014; Lavin et al. 2014). For instance, comparing the enhancer landscape of microglia to that of large peritoneal macrophages revealed that 60% of the active enhancers are shared, but 40% are macrophage subset-specific (Gosselin et al. 2014). Cell type specificity is more striking when considering SEs, consistent with work by other groups suggesting that these regulatory elements are critical to cell identity (Hnisz et al. 2013; Gosselin et al. 2014; Adam et al. 2015).

By removing macrophages from their environment and putting them into tissue-culture conditions, ~50% of the enhancers remained unchanged, but only 26% of SEs still met the SE criteria (Gosselin et al. 2014). This further supports the hypothesis that SEs are uniquely regulated

Figure 2. Schematic overview of the interplay between primed enhancers established by lineage-determining transcription factors (LDTFs) and activation by signals from the environment. Environment-specific signals activate a subset of enhancers that are primed in all macrophages. This leads to the expression of environment-induced genes, a subset of which encodes collaborative TFs. These TFs in turn drive the establishment of tissue-specific enhancers in collaboration with already expressed LDTFs, such as PU.1. The combination of direct and indirect responses contributes to the identity and function of macrophages residing in that particular tissue environment.

genomic regions that are sensitive to environment and determine the fate of the cell type.

Computational analyses showed that macrophage subset-specific enhancers display very distinct enrichment of DNA motifs recognized by SDTFs. These include SMAD motifs in microglia-specific enhancers, GATA6 and RAR β in large peritoneal macrophages, PPAR γ in alveolar macrophages, LXR α in Kupffer cells, etc. (Gosselin et al. 2014; Lavin et al. 2014). Of note, natural genetic variation analyses implicated SMAD and GATA6 as collaborative factors with PU.1 to select microglia-specific and large peritoneal macrophage-specific enhancers, respectively (Gosselin et al. 2014).

These analyses suggested that different combinations of SDTFs might cause the subset specificity of the enhancer repertoire of different populations of resident-tissue macrophages. Lavin et al. (2014) provided a compelling demonstration of the role of environment in supplying key signals to activate SDTFs. Indeed, isolating peritoneal macrophages and transplanting them into the alveolar cavity of the lungs led to a loss of peritoneal macrophage-associated enhancer repertoire and, concomitantly, a gain of an alveolar macrophage-enhancer repertoire. These effects were paralleled by a respective loss of GATA6 motif enrichment and a gain of a PPAR γ motif signature in the reconfigured enhancer landscape.

We provided strong additional evidence for the role of the environment in driving macrophage phenotype while exploring the molecular mechanisms of macrophage subset identity. Tissue macrophages extracted and transferred to an *in vitro* culture environment changed their gene expression program dramatically, resulting in a loss of their original gene signature identity. Importantly, the culture conditions led to a down-regulation of a

significant number of TFs, many of which may act as potential collaborative factors with PU.1. However, supplementing macrophages in vitro with key stimulating ligands has profound effects on their identity. Indeed, supplementing large peritoneal macrophages in culture condition with retinoic acid (RA) maintained a significant proportion of the features of their original in vivo enhancer repertoire and gene expression program. On the other hand, adding Tgf- β 1 to the media polarized peritoneal macrophages in culture toward a microglia in vivo phenotype. These observations are highly consistent with previous studies that reported that RA and Tgf- β 1 are key factors for the ontogeny and/or functions of large peritoneal macrophages and microglia, respectively (Makwana et al. 2007; Butovsky et al. 2014; Okabe and Medzhitov 2014).

These latter experiments suggested that a macrophage's subset identity is the product of an elaborate molecular cascade. Indeed, the *Rarb* gene locus is primed in microglia, but displays a SE phenotype in large peritoneal macrophages, which is concordant with the observation that RA promotes Rar β expression in a positive feedback manner (de Thé et al. 1990). Of importance, high expression of Rar β then promotes expression of numerous TFs, including Gata6, Nfe2, Bhlhe40, which can in turn function in a collaborative manner with PU.1 to precisely expand the functional enhancer repertoire and gene expression program of large peritoneal macrophages. Therefore, such a chain of events, involving the integration of tissue environment-derived factors with DNA, provides an elegant and highly specific mechanism for the establishment of the identity of the different resident tissue macrophage subsets (Fig. 2).

INTERSECTION OF EPIGENOMIC CONCEPTS WITH GWAS DATA

The technical and conceptual advances in epigenomics described above provide a powerful means to contextualize work in the field of medical genetic research on a genome-wide level. A significant dividend of the efforts to understand how enhancer selection proceeds and more general principles of epigenomic control of gene regulation is already the appreciation that natural genetic variation impacts gene expression through effects on DNA regulatory elements (Dimas et al. 2009; Pomerantz et al. 2009; Ernst et al. 2011; Harismendy et al. 2011; Maurano et al. 2012; Sanyal et al. 2012; Schaub et al. 2012; Hnisz et al. 2013; Farh et al. 2015; Marson et al. 2015). Importantly, these studies also highlighted that the majority of single-nucleotide polymorphisms (SNPs) found to be associated with disease risk by genome-wide association studies (GWASs) are in noncoding regions of the genome and frequently map within regulatory elements active predominantly in cell types relevant to the disease (Dimas et al. 2009; Hu et al. 2011). For example, SNPs that confer susceptibility for autoimmune diseases like multiple sclerosis and rheumatoid arthritis are prevalent within T-cell enhancers (Okada et al. 2014). Furthermore, risk SNPs are enriched in regions of TF binding, suggesting that

disruption of TF–DNA interactions may be a primary mode of actions for noncoding SNPs that are clinically relevant (Fig. 3A; Ernst et al. 2011; Maurano et al. 2012; Kilpinen et al. 2013). Of note, such a mode of action for SNPs has also been reported for other complex diseases, including metabolic disorders (Soccio et al. 2015) and coronary artery diseases (Harismendy et al. 2011). Several studies also showed that sequence variation associated with disease is especially enriched in SEs of disease-relevant cell types (Hnisz et al. 2013; Parker et al. 2013). SEs are very sensitive to perturbations (Siersbæk et al. 2014) and changes in environment (Gosselin et al. 2014; Adam et al. 2015) and are therefore a good target for disease-associated SNPs.

Although very informative, these early studies could not discriminate between actual causal SNPs and neutral/noncausal SNPs that emerged as potential candidates because of linkage disequilibrium. However, according to recent estimates, 90% of causal SNPs associated with autoimmune diseases map onto noncoding regions of the genome, and 60% of those localize within immune-cell enhancers (Farh et al. 2015). Unexpectedly, data from this study also indicated that disruptive SNPs might not necessarily interfere with TF–DNA interactions. Indeed, SNPs did not map within TF motifs and were instead located in their vicinity. Thus, the mechanism disrupted by causal SNPs is difficult to interpret by current paradigms in epigenomics.

This latter observation by Farh et al. (2015) points to a critical role for the “DNA context” within enhancers in regulating their functions optimally. For example, chromosomal rearrangements of only one enhancer can cause dysregulation of two specific acute myeloid leukemia (AML) predisposition genes (Gröschel et al. 2014). Evidence also suggests that SNPs lying outside of TF motifs can affect chromatin looping (Grubert et al. 2015). Thus, although enhancers serve as platforms for the integration of SDTFs binding with DNA and the transcription machinery, their proper functions may require more than simple local coordinated enrichment of DNA motifs recognized by TFs. The nature of the additional mechanism(s) involved in enhancer functions remains quite elusive and may relate to transcriptional processes and/or eRNA synthesis. We note also that our comprehension of the biochemical principles guiding TF–DNA interactions remains rudimentary. In this regard we recently reported that under certain circumstances DNA variance within a TF motif appears to have limited influence in driving differential TF–DNA interactions at a similar regulatory element between two different strains of mice, as is the case of recruitment of the RelA/p65 subunit of NF- κ B at macrophage enhancers following TLR4 activation (Heinz et al. 2013).

CONSERVATION AND RELEVANCE TO HUMAN DISEASES

DNA sequences at enhancers and other regulatory elements display a relatively high level of conservation across mammalian species (Fig. 3B; Göke et al. 2011;

Figure 3. Implications of mechanisms of enhancer selection and function for interpretation of genome-wide association studies (GWASs). (A) Schematic overview illustrating how single-nucleotide polymorphisms (SNPs) identified in GWASs and associated with expression quantitative trait loci (eQTLs) can affect enhancers in a cell type-specific manner. (B) Schematic overview shows how studies identifying disease-associated genomic variations in mouse can be helpful in understanding human disease through conserved sequence.

Cheng et al. 2014), although it has to be noted that the same enhancer potentially can have different regulatory outcomes (Yan et al. 1997). Nevertheless, leveraging the conservation between species can inform about the etiology and/or maintenance/pathological mechanisms that contribute to diseases.

Studies using a mouse model of Alzheimer's disease (AD) that display chronic neurodegeneration provide an elegant example of such application of epigenomics (Gjoneska et al. 2015). In such a model, as neurons die, accompanying activity of de novo enhancers emerge at the whole-tissue level. Of note, these enhancers show a significant enrichment for the DNA motif recognized by PU.1, and the DNA sequences encompassing these de novo PU.1 enhancers are well conserved in humans. Strikingly, however, they also display features of active and/or primed enhancers in CD14⁺ human monocytes, a cell type previously implicated in the etiology of AD by independent studies (Bradshaw et al. 2013).

That a complex amalgam of signals triggered by neuronal death and distress elicits an immune response that implicates DNA sequences and regulatory elements that are conserved across species in related myeloid cells is quite provocative. Furthermore, refinements of the acquisition of data in this model (e.g., by extracting specifically brain microglia as the brain degenerates) can potentially lead to clearer resolution of the data. This could prove to be helpful to deconvolute the signaling pathways

whose activity becomes integrated with that of PU.1 to activate the de novo regulatory elements. Finally, we note that previous expression quantitative trait locus (eQTL) studies associated monocytes, but not T cells, with neurodegenerative diseases, including Alzheimer's and Parkinson's diseases (Raj et al. 2014). Overall, this raises the intriguing possibility that the role of candidate mutations identified in GWAS and eQTL studies can be interrogated in complex settings using the relevant model of human disease (Fig. 3).

CONCLUSION AND PERSPECTIVE

Through epigenomics and next-generation sequencing technologies, we now possess powerful tools to explore and appreciate the mechanisms through which a cell's environment influences how genetics information is interpreted by cells to achieve identity and function. Despite recent discoveries, however, many outstanding questions remain. With regard to macrophages, it is not clear whether different developmental origins (i.e., primitive vs. definitive hematopoiesis) can have residual effects on their transcriptional programs. Specifically, do enhancers relevant to monocyte but not to resident tissue macrophage become silent, or are they erased, as monocytes differentiate, for example, into Kupffer cells, cardiac macrophages, or resident peritoneal macrophage? On the other hand, for macrophage populations that do

not depend on monocytes to be maintained like microglia, how does the aging process affect their epigenome and/or ability to optimally regulate their gene expression programs? Finally, the ability to infer signaling pathway activity from activation or inhibition of DNA regulatory elements is a powerful lever to gain a better understanding of signals that promote homeostasis or drive disease mechanism. Therefore, application of these tools will help us gain a better understanding of macrophage activation and functions as it applies to any in vivo contexts, including human diseases.

ACKNOWLEDGMENTS

We thank Leslie Van Ael for her assistance with figure and manuscript preparation. These studies were primarily supported by National Institutes of Health (NIH) grants DK091183, CA17390, and DK063491 and the San Diego Center for Systems Biology (GM085764). David Gosselin is supported by a fellowship from the Multiple Sclerosis Society of Canada.

REFERENCES

- Adam RC, Yang H, Rockowitz S, Larsen SB, Nikolova M, Oristian DS, Polak L, Kadaja M, Asare A, Zheng D, et al. 2015. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. *Nature* **521**: 366–370.
- Banerji J, Rusconi S, Schaffner W. 1981. Expression of a β -globin gene is enhanced by remote SV40 DNA sequences. *Cell* **27**: 299–308.
- Barish GD, Yu RT, Karunasiri M, Ocampo CB, Dixon J, Benner C, Dent AL, Tangirala RK, Evans RM. 2010. Bcl-6 and NF- κ B cistromes mediate opposing regulation of the innate immune response. *Genes Dev* **24**: 2760–2765.
- Barozzi I, Simonatto M, Bonifacio S, Yang L, Rohs R, Ghisletti S, Natoli G. 2014. Coregulation of transcription factor binding and nucleosome occupancy through DNA features of mammalian enhancers. *Mol Cell* **54**: 844–857.
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007. High-resolution profiling of histone methylations in the human genome. *Cell* **129**: 823–837.
- Bossard P, Zaret KS. 1998. GATA transcription factors as potential regulators of gut endoderm differentiation. *Development* **125**: 4909–4917.
- Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboyva S, Lee M, Von Korff A, et al. 2013. CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. *Nat Neurosci* **16**: 848–850.
- Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglspenger T, Dake B, Wu PM, Doykan CE, et al. 2014. Identification of a unique TGF- β -dependent molecular and functional signature in microglia. *Nat Neurosci* **17**: 131–143.
- Calo E, Wysocka J. 2013. Modification of enhancer chromatin: What, how, and why? *Mol Cell* **49**: 825–837.
- Carr A, Biggin MD. 1999. A comparison of in vivo and in vitro DNA-binding specificities suggests a new model for homeoprotein DNA binding in *Drosophila* embryos. *EMBO J* **18**: 1598–1608.
- Cheng Y, Ma Z, Kim BH, Wu W, Cayting P, Boyle AP, Sundaram V, Xing X, Dogan N, Li J, et al. 2014. Principles of regulatory information conservation between mouse and human. *Nature* **515**: 371–375.
- Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, et al. 2010. Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc Natl Acad Sci* **107**: 21931–21936.
- DeKoter RP, Walsh JC, Singh H. 1998. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. *EMBO J* **17**: 4456–4468.
- de Thé H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. 1990. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene. *Nature* **343**: 177–180.
- D'haeseleer P. 2006. What are DNA sequence motifs? *Nat Biotechnol* **24**: 423–425.
- Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Gutierrez Arcelus M, Sekowska M, et al. 2009. Common regulatory variation impacts gene expression in a cell type-dependent manner. *Science* **325**: 1246–1250.
- ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**: 57–74.
- Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, Ivanov S, Satpathy AT, et al. 2014. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity* **40**: 91–104.
- Ernst J, Kheradpour P, Mikkelsen TS, Shores N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, et al. 2011. Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473**: 43–49.
- Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shores N, Whitton H, Ryan RJ, Shishkin AA, et al. 2015. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* **518**: 337–343.
- Gautier EL, Shay T, Miller J, Greter M, Jakubczik C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, et al. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* **13**: 1118–1128.
- Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. 2010. Development of monocytes, macrophages, and dendritic cells. *Science* **327**: 656–661.
- Ghisletti S, Barozzi I, Mietton F, Polletti S, De Santa F, Venturini E, Gregory L, Lonie L, Chew A, Wei CL, et al. 2010. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. *Immunity* **32**: 317–328.
- Ginhoux F, Jung S. 2014. Monocytes and macrophages: Developmental pathways and tissue homeostasis. *Nat Rev Immunol* **14**: 392–404.
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* **330**: 841–845.
- Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, Kellis M. 2015. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. *Nature* **518**: 365–369.
- Göke J, Jung M, Behrens S, Chavez L, O'Keeffe S, Timmermann B, Lehrach H, Adjaye J, Vingron M. 2011. Combinatorial binding in human and mouse embryonic stem cells identifies conserved enhancers active in early embryonic development. *PLoS Comput Biol* **7**: e1002304.
- Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F, et al. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* **159**: 1327–1340.
- Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, et al. 2014. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell* **157**: 369–381.

- Grubert F, Zaugg JB, Kasowski M, Ursu O, Spacek DV, Martin AR, Greenside P, Srivas R, Phanstiel DH, Pekowska A, et al. 2015. Genetic control of chromatin states in humans involves local and distal chromosomal interactions. *Cell* **162**: 1051–1065.
- Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, Deswarte K, Malissen B, Hammad H, Lambrecht BN. 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* **210**: 1977–1992.
- Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL. 2011. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. *Cell* **145**: 622–634.
- Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, et al. 2011. 9p21 DNA variants associated with coronary artery disease impair interferon- γ signalling response. *Nature* **470**: 264–268.
- Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, et al. 2007. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat Genet* **39**: 311–318.
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**: 576–589.
- Heinz S, Romanoski CE, Benner C, Allison KA, Kaikkonen MU, Orozco LD, Glass CK. 2013. Effect of natural genetic variation on enhancer selection and function. *Nature* **503**: 487–492.
- Heinz S, Romanoski CE, Benner C, Glass CK. 2015. The selection and function of cell type-specific enhancers. *Nat Rev Mol Cell Biol* **16**: 144–154.
- Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. *Cell* **155**: 934–947.
- Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B, Leboeuf M, Low D, Oller G, Almeida F, et al. 2012. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. *J Exp Med* **209**: 1167–1181.
- Hu X, Kim H, Stahl E, Plenge R, Daly M, Raychaudhuri S. 2011. Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. *Am J Hum Genet* **89**: 496–506.
- Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO. 2001. Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. *Nature* **409**: 533–538.
- Johnson SD, Mortazavi AM, Myers RM, Wold B. 2007. Genome-wide mapping of in vivo protein–DNA interactions. *Science* **316**: 1497–1502.
- Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, Chun HB, Tough DF, Prinjha RK, Benner C, et al. 2013. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. *Mol Cell* **51**: 310–325.
- Kazemian M, Pham H, Wolfe SA, Brodsky MH, Sinha S. 2013. Widespread evidence of cooperative DNA binding by transcription factors in *Drosophila* development. *Nucleic Acids Res* **41**: 8237–8252.
- Kilpinen H, Waszak SM, Gschwind AR, Raghav SK, Witwicki RM, Orioli A, Migliavacca E, Wiederkehr M, Gutierrez-Arcelus M, Panousis NI, et al. 2013. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. *Science* **342**: 744–747.
- Lam MT, Cho H, Lesch HP, Gosselin D, Heinz S, Tanaka-Oishi Y, Benner C, Kaikkonen MU, Kim AS, Kosaka M, et al. 2013. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. *Nature* **498**: 511–515.
- Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* **159**: 1312–1326.
- Lee CS, Friedman JR, Fulmer JT, Kaestner KH. 2005. The initiation of liver development is dependent on Foxa transcription factors. *Nature* **435**: 944–947.
- Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, Merkurjev D, Zhang J, Ohgi K, Song X, et al. 2013. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. *Nature* **498**: 516–520.
- Lupien M, Eeckhoutte J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. 2008. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. *Cell* **132**: 958–970.
- Makwana M, Jones LL, Cuthill D, Heuer H, Bohatschek M, Hristova M, Friedrichsen S, Ormsby I, Bueringer D, Koppius A, et al. 2007. Endogenous transforming growth factor β 1 suppresses inflammation and promotes survival in adult CNS. *J Neurosci* **27**: 11201–11213.
- Marson A, Housley WJ, Hafner DA. 2015. Genetic basis of autoimmunity. *J Clin Invest* **125**: 2234–2241.
- Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al. 2012. Systematic localization of common disease-associated variation in regulatory DNA. *Science* **337**: 1190–1195.
- McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, et al. 1996. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. *EMBO J* **15**: 5647–5658.
- McPherson CE, Shim EY, Friedman DS, Zaret KS. 1993. An Active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array. *Cell* **75**: 387–398.
- Okabe Y, Medzhitov R. 2014. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell* **157**: 832–844.
- Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, et al. 2014. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **506**: 376–381.
- Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, Curina A, Prosperini E, Ghisletti S, Natoli G. 2013. Latent enhancers activated by stimulation in differentiated cells. *Cell* **152**: 157–171.
- Parker SC, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, van Bueren KL, Chines PS, Narisu N, NISC Comparative Sequencing Program, et al. 2013. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. *Proc Natl Acad Sci* **110**: 17921–17926.
- Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, et al. 2009. The 8q24 cancer risk variant rs6983267 shows long-range interaction with *MYC* in colorectal cancer. *Nat Genet* **41**: 882–884.
- Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, et al. 2014. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science* **344**: 519–523.
- Sanyal A, Lajoie BR, Jain G, Dekker J. 2012. The long-range interaction landscape of gene promoters. *Nature* **489**: 109–113.
- Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. 2012. Linking disease associations with regulatory information in the human genome. *Genome Res* **22**: 1748–1759.
- Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, et al. 2012. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* **336**: 86–90.
- Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, Tsirka SE, Maletic-Savatic M. 2010. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell* **7**: 483–495.

- Siersbæk R, Rabiee A, Nielsen R, Sidoli S, Traynor S, Loft A, La Cour Poulsen L, Rogowska-Wrzesinska A, Jensen ON, Mandrup S. 2014. Transcription factor cooperativity in early adipogenic hotspots and super-enhancers. *Cell Rep* **7**: 1443–1455.
- Soccio RE, Chen ER, Rajapurkar SR, Safabakhsh P, Marinis JM, Dispirito JR, Emmett MJ, Briggs ER, Fang B, Everett LJ, et al. 2015. Genetic variation determines PPAR γ function and anti-diabetic drug response in vivo. *Cell* **162**: 33–44.
- Step SE, Lim HW, Marinis JM, Prokesch A, Steger DJ, You SH, Won KJ, Lazar MA. 2014. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPAR γ -driven enhancers. *Genes Dev* **28**: 1018–1028.
- Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**: 307–319.
- Yan Y, Jones CA, Sigmund CD, Gross KW, Catanzaro DF. 1997. Conserved enhancer elements in human and mouse renin genes have different transcriptional effects in As4.1 cells. *Circ Res* **81**: 558–566.
- Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, Struhl K. 2006. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. *Mol Cell* **24**: 593–602.
- Yin L, Lazar MA. 2005. The orphan nuclear receptor Rev-erb α recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. *Mol Endocrinol* **19**: 1452–1459.
- Zamir I, Harding HP, Atkins GB, Hörlein A, Glass CK, Rosenfeld MG, Lazar MA. 1996. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. *Mol Cell Biol* **16**: 5458–5465.

Cold Spring Harbor Symposia on Quantitative Biology

Mechanisms Underlying the Selection and Function of Macrophage-Specific Enhancers

Verena M. Link, David Gosselin and Christopher K. Glass

Cold Spring Harb Symp Quant Biol 2015 80: 213-221 originally published online November 18, 2015

Access the most recent version at doi:[10.1101/sqb.2015.80.027367](https://doi.org/10.1101/sqb.2015.80.027367)

References

This article cites 73 articles, 21 of which can be accessed free at:
<http://symposium.cshlp.org/content/80/213.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>